Vitiligo Skin and Connective Tissue Diseases
Conditions
Interventions
This multinational, cross-sectional exploratory survey study will be conducted across three countries at the Amsterdam UMC, National University Singapore, Cairo University and Ain Shams University. Th
Sponsors
Amsterdam University Medical Centers
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Physician-based diagnosis of non-segmental vitiligo 2. Aged 18 years or above 3. Had a treatment visit at the dermatology department in the past 2 years
Exclusion criteria
Exclusion criteria: Non segmental vitiligo
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The following primary outcome measures are assessed at one time point after treatment: 1. The extent to which shared decision-making (SDM) is experienced will be measured using the validated nine-item Shared Decision-Making Questionnaire (SDM-Q) 2. The extent to which patients want to be involved in the SDM process will be measured using the validated Control Preference Scale 3. The uncertainty patients experience when making healthcare decisions will be measured using the Decisional Conflict Scale 4. Potential shortcomings patients may encounter during their treatment for vitiligo measured using a 5-point Likert scale (ranging from strongly disagree to strongly agree) | — |
Secondary
| Measure | Time frame |
|---|---|
| There are no secondary outcome measures | — |
Countries
Egypt, Netherlands, Singapore
Contacts
Public ContactAlbert Wolkerstorfer
Outcome results
None listed